Managing Runway Pressure Without Panic
Every clinical-stage biopharma company will, at some point, face a board meeting where someone puts up a slide showing 12 to 18 months of remaining cash. When that slide appears, the atmosphere in the room shifts. Decisions that were being made on the basis of science and strategy start being made on the basis of survival. That shift is natural, but if the board does not manage it deliberately, it leads to a cascade of bad decisions that can destroy more value than the cash shortage itself.
The companies that navigate runway pressure well are not the ones that avoid it — almost no clinical-stage company avoids it entirely. They are the ones whose boards have built a framework for capital-constrained decision-making before the pressure arrives.
Why Runway Pressure Distorts Governance
Cash pressure creates a specific kind of dysfunction in the boardroom. It collapses time horizons, narrows the field of options that feel available, and shifts the balance of power between management and investors in ways that are rarely discussed openly.
When a company has three years of cash, the board can afford to think strategically. When it has 14 months, every decision gets filtered through a single question: does this help us raise the next round? That filter is not inherently wrong — survival is a prerequisite for everything else — but it systematically biases decisions toward short-term optics over long-term value creation.
A program that might produce transformative data in 24 months gets deprioritized in favor of a program that can generate a catalyst in 9 months, even if the 24-month program has higher expected value. A partnership that would be favorable in a year gets pursued immediately at worse terms because the company needs the milestone payment. Headcount gets cut in ways that preserve cash but eliminate capabilities the company will need after the raise.
These are not irrational decisions. They are rational responses to a constraint. But the board's job is to ensure that the constraint is being managed rather than managing the company.
The 18-Month Conversation
The single most important governance practice for managing runway pressure is starting the conversation early. Specifically, the board should begin substantive capital planning discussions when the company has at least 18 months of cash remaining. Not 12 months. Not when the CEO raises it. Eighteen months.
The reason is arithmetic. A fundraising process for a clinical-stage company — from the decision to raise through term sheet through closing — typically takes six to nine months. If the company waits until it has 12 months of runway to begin, it is effectively negotiating with six months or less of cash behind it. Every sophisticated investor can see that timeline, and it shows up in the terms.
At 18 months, the board should be asking management a specific set of questions. What is the current monthly burn rate, and what assumptions drive it? What milestones can be achieved before cash runs out under the current plan? What is the minimum raise needed to reach the next value-inflection point? What is the fundraising environment for companies at this stage and in this therapeutic area? And critically, what changes to the operating plan could extend the runway by three to six months without materially damaging the company's prospects?
These questions are not about triggering a fundraise. They are about ensuring the board has the information to make that decision at the right time rather than being forced into it.
The Operating Plan Conversation
When runway pressure emerges, the instinct is to immediately focus on fundraising. This is usually premature. Before discussing how to raise capital, the board should examine whether the current operating plan is appropriately calibrated to the company's capital position.
This is a governance conversation, not a management conversation. The CEO and management team will naturally resist reductions to the operating plan because those reductions mean slower progress, lost team members, and delayed milestones. That resistance is appropriate — it is management's job to advocate for the resources they believe the company needs. It is the board's job to evaluate whether the pace of spending is justified given the capital available and the fundraising environment.
The relevant question is not "can we cut costs?" The answer is always yes. The relevant question is "which costs, if reduced, would extend runway without disproportionately reducing the company's value at the time of the next raise?"
This requires a surprisingly granular conversation for a board-level discussion. The board needs to understand which programs are generating the data that will drive the next financing, which programs are supporting rather than driving value, and which operating costs are fixed versus discretionary. In my experience, most clinical-stage companies have more flexibility in their operating plans than their management teams initially present. Not because management is being dishonest, but because the team that built the plan built it to achieve everything on the roadmap, and nobody asked them to build a version that achieves the critical things with less.
The board should ask management to present two or three operating plan scenarios: the current plan, a plan that extends runway by three months, and a plan that extends runway by six months. Each should include what milestones are preserved, what is deferred, and what the implications are for the next financing. This gives the board a real decision to make rather than a binary choice between the current plan and panic.
Fundraising Under Pressure: What the Board Controls
Once the decision to raise capital is made, the board's governance role shifts. The board is not running the fundraising process — that is management's job — but the board controls several decisions that have an outsized impact on the outcome.
The first is valuation expectations. Boards of companies under runway pressure frequently struggle with valuation. If the last round was at a $200 million post-money valuation and the data since then has been mixed, accepting a $120 million valuation in the next round feels like failure. This emotional response to down rounds leads boards to delay fundraising, reject reasonable offers, and ultimately raise at worse terms than they would have gotten if they had moved earlier.
The board's job is to evaluate whether the proposed valuation reflects the current risk-adjusted value of the company, not whether it reflects the valuation the board wishes the company had. Down rounds are not governance failures. Down rounds that happen because the board delayed fundraising for three months trying to avoid a down round — those are governance failures.
The second decision the board controls is the composition of the investor syndicate. Under pressure, there is a temptation to take money from whoever offers it. This can lead to accepting investors whose interests are misaligned with the existing shareholder base, whose governance expectations conflict with the board's approach, or whose reputation in the market sends a negative signal. The board should evaluate incoming investors with the same rigor it would apply when the company is not under pressure, even though the timeline is compressed.
The third decision is the size of the raise. Companies under runway pressure tend to raise the minimum amount needed to reach the next milestone. This is understandable but risky. If the milestone is not achieved, or if it takes longer than expected, the company is immediately back in the same position. The board should push for a raise that provides a meaningful buffer beyond the next milestone — typically 18 to 24 months of runway at the projected burn rate — even if that means accepting more dilution.
What the Board Should Not Do
Runway pressure creates an environment where boards are tempted to overstep their governance role. There are several common patterns that boards should consciously avoid.
Micromanaging the fundraising process is the most frequent. When cash is short, some boards want weekly updates on every investor conversation, want to approve every term sheet change, and want to participate in investor meetings. This slows the process, signals dysfunction to potential investors, and undermines the CEO's ability to negotiate effectively. The board should set the parameters — acceptable valuation range, minimum raise amount, investor criteria — and then let management execute.
Making operating decisions that belong to management is the second pattern. Under pressure, boards sometimes start directing which programs to cut, which employees to let go, and which expenses to eliminate. This crosses the governance line. The board should define the financial constraints and the strategic priorities. Management should determine how to operate within those constraints.
Negotiating with individual investors outside the formal process is the third pattern, and it is the most dangerous. When board members who are also investors begin having side conversations with potential new investors, it creates information asymmetry, potential conflicts of interest, and confusion about who is representing the company. All investor discussions should flow through the CEO and CFO, with the board informed through proper channels.
The Emotional Dimension
This is rarely discussed in governance literature, but runway pressure is emotionally taxing for everyone involved. The CEO is worried about making payroll and keeping the team together. The existing investors are worried about their investment. The independent directors are worried about their fiduciary duties. The scientific team is worried about their programs being cut.
The board's emotional tone during this period matters more than most directors realize. A board that projects panic — calling emergency meetings, making dramatic changes to the operating plan, publicly second-guessing management — sends signals that make fundraising harder. A board that projects disciplined urgency — acknowledging the constraint, setting clear priorities, maintaining regular governance cadence — sends signals that attract the kind of investors the company wants.
This is not about pretending the situation is comfortable when it is not. It is about demonstrating that the board and management have a plan, are executing against it, and are making rational decisions under pressure. That is exactly what a prospective investor wants to see.
Building the Framework Before You Need It
The worst time to develop a framework for managing runway pressure is when the pressure has already arrived. Boards that handle this well are the ones that have established practices during calmer periods.
This means building regular cash forecasting into every board meeting, not just when cash is low. It means having a standing discussion about the fundraising environment so the board is informed about market conditions before they need to act. It means establishing the board's role in capital decisions explicitly, so that when the moment comes, everyone knows who decides what.
Most importantly, it means having an honest conversation about the company's capital position before it becomes urgent. The board that discusses runway at 24 months and again at 18 months and again at 15 months will make better decisions at 12 months than the board that sees the issue for the first time when the slide goes up showing a year of cash remaining.
Runway pressure is not a crisis unless the board allows it to become one. Managed deliberately, it is simply another constraint that clinical-stage companies navigate on the way to creating value. The boards that treat it that way — as a constraint to be managed rather than a crisis to be survived — consistently produce better outcomes for their companies and their shareholders.